TAIPEI, Taiwan – Diminutive drug discovery firm PRISM Pharma Co. Ltd., of Yokohama, Japan, has closed a Series C round of funding of approximately ¥1.4 billion (US$15 million) with the funds earmarked for upcoming clinical trials for the company's investigative oncology drug PRI-724 in non-oncology related conditions, initially fibrosis.